EpiEndo Pharmaceuticals: EpiEndo reports Phase 2A results for lead asset, EP395, in COPD finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
REYKJAVIK, Iceland, April 10, 2024 EpiEndo Pharmaceuticals (‘EpiEndo’ or the ‘Company’), a clinical-stage biopharmaceutical company developing a new class of oral, barrier-enhancing, anti-inflammatory therapeutics addressing chronic airway diseases, announces the successful completion of its Phase 2A clinical trial for EP395 in patients diagnosed with Chronic Obstructive Pulmonary Disease (COPD).
Regulatory approval for first patient study of first non-antibiotic macrolideREYKJAVIK, Iceland, November 14, 2022 / B3C newswire / EpiEndo Pharmaceuticals (‘EpiEndo’), the clinical-stage biopharmaceutical company developing therapeutics for chronic inflammatory diseases, has received regulatory approval to.
Regulatory approval for first patient study of first non-antibiotic macrolide EpiEndo Pharmaceuticals ('EpiEndo'), the clinical-stage biopharmaceutical company developing therapeutics for chronic